Boston Scientific Corporation $BSX Shares Sold by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI decreased its holdings in Boston Scientific Corporation (NYSE:BSX) by 1.2% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 15,573 shares of the medical equipment provider’s stock after selling 190 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Boston Scientific were worth $1,673,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Sound Income Strategies LLC grew its position in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares during the last quarter. 1248 Management LLC acquired a new position in Boston Scientific in the first quarter worth approximately $26,000. Y.D. More Investments Ltd acquired a new position in Boston Scientific in the first quarter worth approximately $27,000. Oliver Lagore Vanvalin Investment Group acquired a new position in Boston Scientific in the second quarter worth approximately $37,000. Finally, Activest Wealth Management boosted its stake in Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 373 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on BSX shares. BTIG Research raised their price objective on shares of Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 1st. Barclays raised their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a research note on Monday, September 29th. Finally, UBS Group raised their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and an average target price of $120.71.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $17,972,457 over the last quarter. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 1.9%

Shares of NYSE:BSX opened at $95.41 on Friday. The firm has a fifty day moving average of $101.98 and a two-hundred day moving average of $101.87. The firm has a market capitalization of $141.38 billion, a P/E ratio of 56.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.